Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse

BACKGROUND The aim of this study was to evaluate the effects of administration of the somatostatin analog RC‐160 (vapreotide) at the time of relapse in patients with androgen independent prostate cancer. METHODS Our study included 13 patients with biopsy‐proven prostate cancer, stage D3. Eight patie...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate 2003-08, Vol.56 (3), p.183-191
Main Authors: Barcena, David González, Schally, Andrew V., Buenfil, Manuel Vadillo, Morales, Adolfo Cortez, L, Victor Hernández, Cardenas-Cornejo, Imelda, Schally, Ana Maria Comaru
Format: Article
Language:English
Subjects:
Adult
Aged
androgen independent tumors
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacology
Delayed-Action Preparations
growth factors
Health Status
Humans
Male
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Pain
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
remission
Somatostatin - administration & dosage
Somatostatin - adverse effects
Somatostatin - analogs & derivatives
Somatostatin - pharmacology
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND The aim of this study was to evaluate the effects of administration of the somatostatin analog RC‐160 (vapreotide) at the time of relapse in patients with androgen independent prostate cancer. METHODS Our study included 13 patients with biopsy‐proven prostate cancer, stage D3. Eight patients had been treated with a depot formulation of the agonist D‐Trp‐6‐LH‐RH, with a median remission time of 68 (range 48–102 months). Five patients were initially treated by surgical orchiectomy, but relapsed after a median time of 33 months (range 17–91 months). A new remission period with a median duration of 10 months (range 2–29 months) was induced with Ketoconazole in the orchiectomy group. At the relapse time, all the patients received 1 mg of vapreotide t.i.d., by subcutaneous route, in addition to D‐Trp‐6‐LH‐RH, or Ketoconazole in the orchiectomy group. RESULTS Eight of 13 patients demonstrated clinical improvement after 3 months of therapy with vapreotide, six showing a decrease in serum prostate specific antigen (PSA) from 234.5 ± 308.5 to 68.2 ± 60.5 ng/ml (mean decline 71 ± 8%; P 
ISSN:0270-4137
1097-0045
DOI:10.1002/pros.10232